Dabrafenib/Trametinib Regimen

**Semantic type:** Therapeutic or Preventive Procedure

**Definition:** A regimen consisting of dabrafenib and trametinib that can be used in the treatment of cutaneous melanomas, non-small cell lung cancers (NSCLCs), anaplastic carcinoma, central nervous system (CNS), esophageal and esophagogastric junction and gastric cancers, ovarian, fallopian tube and primary peritoneal cancers, follicular, papillary and Hurthle cell thyroid carcinomas, and gallbladder or cholangiocarcinoma, ampullary, small bowel, and pancreatic adenocarcinomas, occult primary adenocarcinoma and squamous cell carcinoma, extrapulmonary poorly differentiated neuroendocrine carcinoma/large or small cell carcinoma/mixed neuroendocrine-non-neuroendocrine neoplasm, salivary gland tumors, gastrointestinal stromal tumors (GIST), and hairy cell leukemia.

**Synonyms:** - Dabrafenib + Trametinib - Dabrafenib Plus Trametinib - Dabrafenib and Trametinib - Dabrafenib-Trametinib Regimen - Dabrafenib/Trametinib - Tafinlar-Mekinist - Tafinlar/Mekinist